IP Library Granted Patent US 11,229,659
Granted Patent B2
US 11,229,659 · App. 16/071,548 · Granted Jan 25, 2022

Compositions with specific oligosaccharides to prevent or treat allergies

Inventors: Carine Blanchard (Le Mont-sur-Lausanne, CH); Chiara Nembrini (Oron-la-Ville, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/702A23L33/135A23L33/21A23L33/40A61K9/0095A61K35/744A61K35/745A61K35/747A61P37/08A23V2002/00A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,659
App. No.
16/071,548
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in preventing and/or treating allergy symptoms in an infant or a young child, by increasing SFCA production, in particular colonic acetate, propionate and/or butyrate, in said infant or young children.

Claims (13)

1. A method for preventing and/or reducing allergy symptoms in an infant or a young child, by increasing short chain fatty acids (SCFA) production in the infant or young child, the method comprising administering a nutritional composition comprising an oligosaccharide mixture to the infant or young child,

the oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, at least one galacto-oligosaccharide and at least one sialylated oligosaccharide, and

the nutritional composition has at least one formulation selected from the group consisting of (i) the at least one N-acetylated oligosaccharide comprises at least one of GalNAcβ1,3Galβ1,4Glc or Galβ1,6GalNAcβ1,4Glc; and (ii) the at least one sialylated oligosaccharide comprises at least one of NeuAcβ2,3Galβ1,4Glc or NeuAcβ2,6Galβ1,4Glc.

2. The method according to claim 1 wherein the reducing of the allergy symptoms comprises treating allergy symptoms in the infant or a young child, by increasing SCFA.

3. The method according to claim 1 , wherein the at least one galacto-oligosaccharide is selected from the group consisting of Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,4Glc, Galβ1,3Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,6Galβ1,4Glc, Galβ1,3Galβ1,6Galβ1,4Glc, Galβ1,6Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,6Galβ1,6Glc, Galβ1,3Galβ1,3Glc, Galβ1,4Galβ1,4Glc, Galβ1,4Galβ1,4Galβ1,4Glc, and mixtures thereof.

4. The method according to claim 1 , wherein the oligosaccharide mixture is present in an amount of from 2.5 to 15.0 wt % of the nutritional composition.

5. The method according to claim 1 comprising at least 0.01 wt % of the at least one N-acetylated oligosaccharide, at least 2.0 wt % of the at least one galacto-oligosaccharide and at least 0.02 wt % of at least one sialylated oligosaccharide.

6. The method according to claim 1 , wherein the nutritional composition further comprises a prebiotic selected from the group consisting of human milk oligosaccharides, fructo-oligosaccharide, inulin, xylooligosaccharides, polydextrose and combinations thereof.

7. The method according to claim 1 , wherein the nutritional composition further comprises a probiotic bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticus, Lactobacillus bulgari, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Streptococcus salivarius, Streptococcus thermophilus, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis , or Bifidobacterium adolescentis and mixtures thereof.

8. The method according to claim 1 , wherein the nutritional composition is an infant formula.

9. The method according to claim 1 , wherein the oligosaccharide mixture is derived from animal milk.

10. The method according to claim 1 , wherein the SCFA is butyrate and/or propionate.

11. The method according to claim 10 , wherein the oligosaccharide mixture is derived from one or more of cow's milk, goat's milk, buffalo's milk, or camel milk.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2019
From: BLANCHARD, CARINE; NEMBRINI, CHIARA
To: NESTEC S.A.
Reel/Frame 049940/0281 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →